A biotech company that specializes in developing novel anti-cancer treatments based on monoclonal antibodies
CellmAbs is a biotech company that specializes in developing novel anti-cancer treatments based on monoclonal antibodies (mAbs) targeting cancer-specific glycans. The company was founded in 2019 as a spin-off from NOVA University of Lisbon and has received funding from two of Portugal’s top life science venture capital firms. CellmAbs has a rapidly expanding team of international and experienced scientists who have developed multiple preclinical candidates for solid tumors. The company collaborates with biotech/pharma companies and clinical institutes to advance its pipeline. CellmAbs aims to provide innovative and effective solutions to treat patients with solid tumors.
- Scrips Top 10 To Watch emerging Biotech companies in Europe 2020;
- JLAbs company NYC, USA.